my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for an extension of the therapeutic indication for the centrally authorised medicine Velcade (bortezomib).On 2 September 2011, Janssen-Cilag International NV submitt more
BioInvent International AB announced that new preclinical data has been presented on its BI-505 programme that demonstrates anti-cancer activity in multiple myeloma and beneficial effect on bone density. The results were presented at the American Society of Hematology (ASH) Annual Meeting.The study more
Aeterna Zentaris Inc. announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer. The trial i more
Bortezomib Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals ) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle ... more
Watchlist
This is where you can add this topic to your personal favourites
© 1997-2023 LUMITOS AG, All rights reserved
